The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Celgene International's oral anti-cancer therapy Pomalidomide. The positive results from the MM-003 study of ...
The US Food and Drug Administration (FDA) has approved a new drug named Pomalyst (pomalidomide) for patients who received and did not respond to prior cancer therapies. Pomalyst, the third drug in a class of immunomodulatory agents ...